MolecureS.A.

Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)

The Independent Data Monitoring Committee (IDMC) recommended continuation of the global Phase II PoC study in patients with active pulmonary sarcoidosis without any changes to the current study protocol. The positive recommendation was issued following the IDMC’s review of the complete safety and efficacy dataset specified for the interim analysis in 30 patients and confirms

Molecure focuses on the most commercially promising projects and closes the RNA program

Molecure is focusing its financial and operational resources on the most promising clinical programs: OATD-01 and OATD-02, as well as on the development of a service using a drug discovery and development tool, co-financed under the FENG program The Company has decided to discontinue the development of the RNA platform and to suspend all research

Invitation to investor meeting 2nd April 2025, 1:00 pm (CET)

Molecure S.A. is pleased to invite you to a meeting dedicated to the presentation of the progress of the ongoing research programmes, in particular clinical trials, as well as the development plans for the next quarters and the discussion of the Company's operational and financial situation for 2024. The meeting will be attended by: –

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibito

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further

Molecure at the threshold of a breakthrough in the treatment of inflammatory and fibrotic diseases. The focus on the most breakthrough therapy and the OATD-01 and OATD-02 clinical trials results in a

Molecure has reduced the number of active projects from seven to five, focusing resources on the most promising assets; Key areas for further development and value building for Molecure are: OATD-01 as a potential breakthrough therapy for the treatment of sarcoidosis and MASH, and OATD-02 in trials in patients with solid tumors. Development of projects

Invitation to investor meeting 16th October 2024, 10:00 am (CET)

Molecure S.A. is pleased to invite you to a meeting to discuss the Company's operational and financial situation following the publication of its Q3 2024 report, in particular the progress of ongoing clinical and preclinical stage research programs and further plans. The expected time of the meeting is about 90 minutes. The meeting will be